Spyre Therapeutics earnings were -$208.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest SYRE earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$44.8M, down 20.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, SYRE reported annual earnings of -$208.0M, with -38.6% growth. The next SYRE earnings date is May 13, 2025.
What were Spyre Therapeutics's earnings last quarter?
On SYRE's earnings call on Invalid Date, Spyre Therapeutics (NASDAQ: SYRE) reported Q1 2025 earnings per share (EPS) of -$0.60, up 16.67% year over year. Total SYRE earnings for the quarter were -$44.77 million. In the same quarter last year, Spyre Therapeutics's earnings per share (EPS) was -$0.72.
The next SYRE earnings call is Invalid Date. Add SYRE to your watchlist to be reminded of Spyre Therapeutics's next earnings date.
Is Spyre Therapeutics profitable or losing money?
As of the last Spyre Therapeutics earnings report, Spyre Therapeutics is currently losing money. Spyre Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$208.93 million, a 42.64% decrease year over year.
What was SYRE's earnings growth in the past year?
As of Spyre Therapeutics's earnings date in Invalid Date, Spyre Therapeutics's earnings has grown year over year. SYRE earnings in the past year totalled -$208.93 million.
What are Spyre Therapeutics's earnings expectations?
The current EPS estimate for Spyre Therapeutics's earnings report in Invalid Date is -$0.84.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.